Financial Performance - The company's revenue for Q3 2025 was ¥2,138,864,925.93, representing a 3.72% increase year-over-year, while the year-to-date revenue decreased by 3.54% to ¥6,091,056,594.53[4] - Net profit attributable to shareholders for Q3 2025 was ¥440,846,798.50, a decrease of 26.16% compared to the same period last year, with a year-to-date net profit decline of 19.97% to ¥1,470,738,960.56[4] - The basic earnings per share for Q3 2025 was ¥0.067, down 25.56% year-over-year, and the diluted earnings per share also decreased by the same percentage[4] - The company reported total operating revenue of ¥6,091,056,594.53 for the current period, a decrease of 3.5% compared to ¥6,314,412,912.62 in the previous period[33] - The company's net profit from investments was ¥269,299,096.88, down from ¥439,917,036.98 in the previous period, reflecting a decline of approximately 38.8%[33] - The net profit for the current period is CNY 1,470,320,036.30, a decrease of 19.99% compared to CNY 1,838,514,042.16 in the previous period[34] - The total comprehensive income for the current period is CNY 1,365,506,628.54, down from CNY 1,685,104,868.09 in the previous period, reflecting a decline of 18.93%[35] - Basic and diluted earnings per share are both CNY 0.222, compared to CNY 0.277 in the previous period, indicating a decrease of 20%[35] - The company's operating profit decreased to CNY 1,744,204,358.95 from CNY 2,261,253,944.01, reflecting a decline of 22.83%[34] Assets and Liabilities - Total assets at the end of Q3 2025 reached ¥38,020,411,474.40, reflecting a 13.05% increase from the end of the previous year[4] - Total assets increased to ¥38,020,411,474.40 from ¥33,631,225,254.06, reflecting a growth of about 13.1%[31] - Total liabilities rose to ¥5,436,804,293.46 from ¥1,690,505,789.91, showing a significant increase, primarily due to long-term borrowings[30] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥690,903,086.19, an increase of 33.99% compared to the previous year[8] - Cash flow from operating activities generated a net amount of CNY 690,903,086.19, an increase of 33.94% from CNY 515,627,395.21 in the previous period[37] - Cash flow from investing activities resulted in a net outflow of CNY 2,671,044,847.28, worsening from a net outflow of CNY 1,113,733,825.29 in the previous period[37] - Cash flow from financing activities generated a net inflow of CNY 1,773,832,354.42, compared to a net outflow of CNY 453,980,207.07 in the previous period, showing a significant improvement[37] - Cash and cash equivalents decreased to ¥2,096,006,316.90 from ¥2,982,705,503.57, representing a decline of approximately 29.7%[28] - The total cash and cash equivalents at the end of the period is CNY 1,129,621,936.26, down from CNY 2,142,061,370.80 at the end of the previous period[37] Shareholder Information - As of September 30, 2025, Haiyingkang (Qingdao) Medical Technology Co., Ltd. holds 1,547,513,352 shares, representing 23.31% of the total share capital[11] - Grifols, S.A. retains 437,069,656 shares, accounting for 6.58% of the total share capital[11] - The total number of shares repurchased by the company as of September 30, 2025, is 68,321,952 shares, which is 1.03% of the total share capital[13] - The total amount spent on share repurchases by the company is approximately RMB 469.85 million[13] - The maximum repurchase price per share is capped at RMB 9.55, with the highest transaction price recorded at RMB 7.09 and the lowest at RMB 6.62[13][14] - Haiyingkang and Grifols, S.A. have formed a concerted action relationship, controlling a combined total of 1,984,583,008 shares, or 29.90% of the total share capital[11] - The top ten shareholders collectively hold significant stakes, with the largest shareholder owning 23.31% of the total shares[11] - The controlling shareholder, Haiyingkang, increased its stake by 72,439,700 shares, representing 1.09% of the total share capital, with a total investment of approximately RMB 496.83 million during the first buyback plan[15] - In the second buyback plan, Haiyingkang acquired 73,042,200 shares, accounting for 1.10% of the total share capital, with a total investment of about RMB 499.86 million[17] - The third buyback plan saw Haiyingkang purchase 72,935,300 shares, also representing 1.10% of the total share capital, with a total investment of approximately RMB 499.99 million[18] - The company plans to use between RMB 250 million and RMB 500 million for share repurchase purposes[12] - The share repurchase program is intended for employee stock ownership plans or equity incentives[12] - The share repurchase lock-up period for Haiyingkang and Grifols, S.A. is set for 36 months following the completion of the transaction[11] Clinical Trials and Product Development - The company received approval for the clinical trial of "SR604 Injection" for hemophilia treatment, with the first phase starting in March 2024[20] - "SR604 Injection" entered the second phase of clinical trials, focusing on safety, tolerability, and effectiveness in hemophilia patients[21] - The company has applied for an additional clinical trial indication for "SR604 Injection" to prevent bleeding in patients with von Willebrand disease, which has been accepted by the regulatory authority[22] - The company has initiated clinical trials for SR604 injection for the prevention of bleeding in patients with von Willebrand disease, with a new application submitted to the National Medical Products Administration[24] - The company has entered the phase IIb trial stage for SR604 injection, having received preliminary safety and efficacy data[24] Asset and Credit Impairment - The company reported a significant increase in accounts receivable, which rose by 63.64% to ¥2,288,582,185.54 due to adjustments in sales credit policies[7] - Accounts receivable increased significantly to ¥2,288,582,185.54 from ¥1,398,534,714.31, marking a rise of about 63.7%[28] - The company reported a credit impairment loss of CNY -43,562,114.27, compared to CNY -32,094,300.41 in the previous period, indicating an increase in credit losses[34] - The company experienced an asset impairment loss of CNY -44,325,502.36, significantly higher than CNY -13,506,413.52 in the previous period[34]

证券代码：002252 证券简称：上海莱士 公告编号：2025-069 上海莱士血液制品股份有限公司关于 第一期员工持股计划锁定期届满暨解锁条件成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）于 2025 年 10 月 24 日召开第六 届董事会第十四次（临时）会议，审议通过了《关于第一期员工持股计划锁定期 届满暨解锁条件成就的议案》，董事会认为公司第一期员工持股计划本次锁定期 解锁条件已成就。根据《关于上市公司实施员工持股计划试点的指导意见》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《公司 第一期员工持股计划》等相关规定，现将情况公告如下： 一、第一期员工持股计划的基本情况 公司于 2023 年 7 月 28 日分别召开了第五届董事会第二十六次（临时）会议 和第五届监事会第十九次会议，审议并通过了《关于<上海莱士血液制品股份有 限公司第一期员工持股计划（草案）>及其摘要的议案》、《关于<上海莱士血液 制品股份有限公司第一期员工持股计划管理办法>的议案》等相关议案，同意公 司实 ...

上海莱士血液制品股份有限公司 关于第六届董事会第十四次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）第六届董事会第十四次（临时） 会议于 2025 年 10 月 18 日以邮件方式发出会议通知，并于 2025 年 10 月 24 日下 午 4 点以现场结合通讯方式召开。 本次会议应出席董事 9 名，亲自出席董事 8 名。董事 Amarant Martínez Carrió 先生因行程冲突未能亲自出席本次会议，委托董事王全立先生出席并行使表决权。 本次会议由公司董事长谭丽霞女士召集和主持，公司监事、高级管理人员等列席 会议。会议的召集、召开与表决程序符合《公司法》和《公司章程》等有关规定。 与会董事经过充分研究和讨论，审议通过了如下议案： 证券代码：002252 证券简称：上海莱士 公告编号：2025-065 除上述现金分红外，本次利润分配公司不送红股，不以公积金转增股本。 1、审议通过《2025 年第三季度报告》 表决结果：9票同意、0票反对、0票弃权。 本议案已经公司第六届董事会审计委员会审议通 ...

Core Viewpoint - The company emphasizes the importance of reasonable investment returns for all shareholders while balancing its development plans and financial status in its dividend policy [1] Group 1 - The company is currently focused on reserving strategic funds to support the future "deproteinization strategy," which is crucial for its strategic transformation [1] - The company aims to lay a solid foundation for long-term development through this strategic transition [1] - Future dividend policies will be planned reasonably, taking into account the balance between company growth and shareholder returns [1]

Core Viewpoint - The company is currently in the trial production phase at its Guangxi facility and aims to gradually increase production capacity after completing trial production and drug registration approval [2]. Group 1: Company Operations - Guangxi facility is in trial production stage and will enhance output once trial production and drug registration are completed [2]. - The company emphasizes that the blood products industry has unique characteristics, with production capacity primarily influenced by plasma collection capabilities and regulatory approvals [2]. - The company is committed to expediting the approval process for Guangxi products to achieve stable operations [2].

Core Insights - The Biotech Economy Index (970038) closed at 2261.4 points, down 0.81%, with a trading volume of 16.635 billion yuan and a turnover rate of 1.19% [1] - Among the index constituents, 19 stocks rose while 30 stocks fell, with Meihao Medical leading the gainers at 6.53% and Prolo Pharma leading the decliners at 5.41% [1] Index Performance - The Biotech Economy Index experienced a decline of 0.81% on the reporting day [1] - The total market capitalization of the index constituents was significant, with major players like Mindray Medical valued at 266.98 billion yuan [1] Top Constituents - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (13.81% weight, 220.20 yuan, -1.51% change, 2669.80 billion yuan market cap) [1] - Changchun High-tech (5.41% weight, 119.11 yuan, -0.97% change, 485.89 billion yuan market cap) [1] - Kanglong Chemical (4.66% weight, 30.96 yuan, +0.29% change, 550.53 billion yuan market cap) [1] - Other notable constituents include Taige Pharmaceutical, Muyuans, and Aimeike, all within the biotech and healthcare sectors [1] Capital Flow - The net outflow of main funds from the Biotech Economy Index constituents totaled 0.893 billion yuan, while retail investors saw a net inflow of 0.75 billion yuan [1] - Specific stocks like Kanglong Chemical and Meihao Medical experienced varying levels of net inflow and outflow from different investor categories [2]

Core Viewpoint - Shanghai Laishi (002252) reported that as of October 10, 2025, the total number of shareholders is 110,316 [1] Summary by Relevant Sections - Company Information - The total number of shareholders for Shanghai Laishi is 110,316 as of the specified date [1]

Core Viewpoint - Shanghai Laishi (002252) has shown a positive trend in financing activities, with a net buying of 3.64 million yuan on October 16, 2025, and a total net buying of 14.29 million yuan over the last three trading days [1][2]. Financing Activities - On October 16, 2025, the financing buy-in was 42.58 million yuan, while the financing repayment was 38.94 million yuan, resulting in a net buy of 3.64 million yuan [1]. - The financing balance reached 1.288 billion yuan, with 13 out of the last 20 trading days showing net buying activity [1][2]. - The financing balance as of October 16, 2025, represented 2.89% of the circulating market value [2]. Margin Trading Activities - On the same day, there was a short selling of 14,000 shares, with a net sell of 10,400 shares after repaying 3,600 shares [2][3]. - The margin trading balance was reported at 4.8554 million yuan, with a total of 723,600 shares remaining in the short selling account [3]. Overall Margin Trading Balance - The total margin trading balance was 1.293 billion yuan on October 16, 2025, reflecting an increase of 3.69 million yuan or 0.29% from the previous day [4]. - The margin trading balance has shown fluctuations, with a notable decrease of 12.25 million yuan on October 13, 2025 [4].

Core Viewpoint - The company is actively advancing the resumption of production at Guangxi Laishi, with all activities progressing according to the disclosed plans and arrangements. Currently, Guangxi Laishi is in the trial production phase [1] Group 1 - The company is focusing on the resumption of operations at Guangxi Laishi [1] - Production activities are proceeding as per the previously disclosed plans [1] - Guangxi Laishi is currently undergoing trial production [1]

Group 1 - The company Shanghai Laishi Blood Products Co., Ltd. announced the progress of its share repurchase plan on October 10, 2025 [1] - The repurchase plan was approved on January 13, 2025, with a total fund of no less than 250 million yuan and no more than 500 million yuan, with a maximum repurchase price of 9.55 yuan per share [2] - As of the end of September 2025, the company had repurchased a total of 70,974,175 shares at a minimum price of 6.62 yuan per share, with a total transaction amount of approximately 469.85 million yuan [3] Group 2 - The company confirmed that the repurchase complies with the established plan and relevant legal regulations, ensuring that no major events affecting the stock price occurred during the repurchase period [4] - The company will continue to advance the repurchase plan based on market conditions and will fulfill information disclosure obligations as required [4]